---
title: Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease
nct_id: NCT00114803
overall_status: COMPLETED
phase: NA
sponsor: "Boston Children's Hospital"
study_type: INTERVENTIONAL
primary_condition: Ulcerative Colitis
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00114803.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00114803"
ct_last_update_post_date: 2007-12-05
last_seen_at: "2026-05-12T06:16:10.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease

**Official Title:** Use of Intranasally Administered Calcitonin in the Treatment of Osteopenia and Osteoporosis in Children, Adolescents and Young Adults With IBD: A Pilot Study

**NCT ID:** [NCT00114803](https://clinicaltrials.gov/study/NCT00114803)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 66
- **Lead Sponsor:** Boston Children's Hospital
- **Collaborators:** Crohn's and Colitis Foundation, National Institutes of Health (NIH)
- **Conditions:** Ulcerative Colitis, Crohn's Disease
- **Start Date:** 2004-01
- **Completion Date:** 2006-10
- **CT.gov Last Update:** 2007-12-05

## Brief Summary

The hypothesis underlying this study is that nasally administered calcitonin will stabilize or improve bone mineral density in young patients with ulcerative colitis or Crohn's disease. Patients who participate will receive either calcitonin or placebo and will have their bone mineral density measured at the start, at nine months, and at 18 months of study. Participants will also receive age appropriate doses of vitamin D and calcium supplements. Other serological measures of vitamin D status will be obtained every 3 months during the study.

## Detailed Description

This is an institutional, randomized, placebo-controlled, double-blind clinical trial to compare the efficacy of intranasally administered calcitonin (plus oral supplements of age-appropriate doses of calcium and vitamin D) with that of placebo nasal spray (plus oral supplements of age-appropriate doses of calcium and vitamin D) in maintaining or improving bone mineral density. Study subjects will be 8 to 22 year old patients with the diagnosis of inflammatory bowel disease (ulcerative colitis and Crohn's disease) and low bone mineral density defined as DXA z score lower than -1.0 SD. Study end-point will be at 18 months after the continuous administration of nasal calcitonin or placebo and supplements as above. Bone mineral density will be measured by dual energy X-Ray absorptiometry (DXA) at the beginning of the study, and then at 9 and 18 months. The study subjects will be evaluated clinically and nutritionally at the beginning of the study, as well as every 3 months for the duration of the study. Laboratory values relevant to calcium homeostasis and bone turnover will be obtained every 3 months.

## Eligibility

- **Minimum age:** 8 Years
- **Maximum age:** 22 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Low bone mineral density as defined
* Age 8 to 22 years
* Diagnosis of Crohn's disease or ulcerative colitis

Exclusion Criteria:

* Receiving calcitonin or biphosphonates, androgens or growth hormone
* Steroid induced fracture in the past
* Pregnant
* Diagnosis of kidney failure, polycystic ovaries syndrome, or malignancy
```

## Interventions

- **Calcitonin nasal spray (salmon)** (DRUG)

## Primary Outcomes

- **Bone mineral density at 18 months**

## Secondary Outcomes

- **Bone mineral density at 9 months**

## Locations (1)

- Children's Hospital Boston, Boston, Massachusetts, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.children's hospital boston|boston|massachusetts|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00114803.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00114803*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*